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Many intracellular nuclear receptors are expressed in human platelets that negatively regulate platelet func-
tion when stimulated by their endogenous ligands.1–12 Retinoid 
X receptors (RXR) (α, β, and γ) regulate transcription and 
expression of specific genes involved in cell proliferation, dif-
ferentiation, and lipid metabolism and are activated by reti-
noids and vitamin A derivatives.13–17 RXR ligands have been 
found to exert cardioprotective effects by reducing atheroscle-
rosis in apolipoprotein E knockout mice,18 and treatment with 
RXR agonists has also been shown to sensitize cells to insulin 
and rescue hyperglycemia and hyperinsulinemia in type 2 dia-
betes mellitus mouse models, highlighting their potential role 
as therapeutics for the treatment of type 2 diabetes mellitus.19
Several recent studies have identified acute, nongenomic 
roles for several members of the nuclear hormone superfam-
ily including RXR.1,3–5,11,20,21 Treatment with nuclear receptor 
ligands is associated with cardioprotective effects, whereas 
ligands for RXR are associated with reduced atherosclerosis 
and inflammation,18 which may be because of regulation of 
platelet activity. 9-cis-retinoic acid (9-cis-RA), which is mar-
keted as Alitretinoin, is used for the treatment of Kaposi sar-
coma and chronic hand eczema, and decreased blood clotting 
is listed as one of its side effects.22,23
Treatment of platelets with RXR ligands has been shown 
to inhibit ADP and thromboxane A2 receptor–induced plate-
let activation via inhibition of Gq.5 However, effects of RXR 
ligands on platelet responses to other receptor agonists (such 
as thrombin and low concentrations of collagen and other 
glycoprotein VI [GPVI] receptor agonists) and integrin αIIbβ3 
function are unknown, and the antithrombotic effects of RXR 
agonists have not be studied.
This study set out to investigate the mechanism by which 
RXR ligands regulate platelet function and thrombus forma-
tion and explore the potential antiplatelet properties of RXR 
ligands. We describe that RXR agonists evoke broad inhibi-
tion of platelet function, resulting in inhibition of thrombus 
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formation in vitro and in vivo. We report that RXR ligands 
increase protein kinase A (PKA) activity via both cAMP and 
nuclear factor κ-light-chain-enhancer of activated B cells 
(NFκB)–dependent mechanisms that have not been described 
for the endogenous agonist of any other nuclear receptor.24
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
Expression and Localization of RXR in Platelets
Here, we confirm protein expression of RXR in both human and 
mouse platelets and Meg01 cells using immunoblot analysis 
(Figure 1A) and also immunohistochemistry (Figure 1B and 1C). 
This is further supported by previously described expression of 
the separate RXR isoforms in both the human and mouse tran-
scriptome and protein expression in human platelets.5,25 Staining 
of platelets with antibodies raised against both RXR isoforms 
and the membrane marker CD41 confirmed the presence of 
RXR in both human and mouse platelets with punctate staining 
throughout the cytosol within resting human platelets, which 
was not altered on platelet activation. Coimmunoprecipitation 
experiments were performed to determine whether RXR could 
form heterodimers with other nuclear receptors in platelets (as 
in other cell types). RXR was found to coimmunoprecipate 
with the peroxisome proliferator–activated receptors (PPARs), 
PPARα, PPARβ, and PPARγ, and LXR (liver X receptor; Figure 
1C), thereby suggesting that RXR can form heterodimers with 
other nuclear receptors in human platelets.
RXR Agonists Inhibit Platelet 
Aggregation to a Range of Agonists
Light transmission aggregometery using human washed 
platelets was used to analyze the effects of the endogenous 
RXR ligands 9-cis-RA, docosahexaenoic acid, and synthetic 
ligand methoprene acid on platelet aggregation. We found that 
9-cis-RA, docosahexaenoic acid, and methoprene acid at the 
concentrations used (10 and 20 µmol/L) did not cause platelet 
aggregation in the absence of platelet agonists (Figure IA in 
the online-only Data Supplement). As shown in Figure 2, pre-
treatment with 9-cis-RA (20 μmol/L) inhibited platelet aggre-
gation to collagen (1 μg/mL; Figure 2A), the GPVI collagen 
receptor–specific agonist, CRP-XL (0.25 μg/mL; Figure 2B), 
and thrombin (0.05 U/mL; Figure 2C) compared with vehicle 
controls (containing 0.1% dimethyl sulfoxide), with ≈60% and 
20% inhibition after stimulation by collagen (and CRP-XL) 
and thrombin, respectively. Treatment with docosahexaenoic 
acid or methoprene acid (10 or 20 μmol/L) also inhibited 
Nonstandard Abbreviations and Acronyms
9-cis-RA 9-cis-retinoic acid
IP prostaglandin I2
NFκB nuclear factor κ-light-chain-enhancer of activated B cells
PKA protein kinase A
PPAR peroxisome proliferator–activated receptor
RXR retinoid X receptor
VASP vasodilator-stimulated phosphoprotein
Figure 1. Expression and localization of retinoid X receptors (RXR) in platelets. Human and mouse washed platelets were (A) lysed in 
(SDS–PAGE) Laemmli sample buffer, separated by SDS–PAGE and transferred to polyvinylidene fluoride (PVDF) membranes before blot-
ting with an antibody that recognizes both α and β isoforms of RXR. Representative blots are shown. B, Human platelets ([i] resting and [ii] 
activated) and (iii) mouse platelets (resting) were fixed in 4% paraformaldehyde and permeabilized with 0.2% Triton-X-100 and stained for 
RXR (in red) and CD41 (in green, as a marker for the platelet membrane) with primary antibodies raised against RXR and CD41. Second-
ary antibodies conjugated to Alexa-647 and Alexa-488 were used to visualize RXR and CD41, respectively. No primary antibody–treated 
samples were also included as a negative control. Representative images shown. C, Human washed platelets lysed in NP40 buffer before 
immunoprecipitation of RXR using 1 µg/mL of primary antibody overnight at 4°C and protein A/G magnetic beads. Pull down samples 
lysed in (SDS–PAGE) Laemmli sample buffer, separated by SDS–PAGE, and transferred to PVDF membranes before blotting with antibod-
ies that recognize different nuclear receptors, including PPARα, PPARγ, and LXR (liver X receptor) and a secondary antibody that does not 
recognize denatured IgG. RXR IgG loaded as a control for IgG contamination. Representative blot shown.
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Figure 2. The effect of retinoid X receptors (RXR) ligands on platelet function. Washed human platelets were pretreated for 10 min with 
increasing concentrations of 9-cis-RA (10 and 20 µmol/L) before stimulation with (A) collagen (1 µg/mL), (B) CRP-XL (0.25 µg/mL), or (C) 
thrombin (0.05 U/mL) and aggregation monitored using optical light transmission aggregometry, (i) representative traces and (ii) quanti-
fied data shown. D, Integrin activation measured as fibrinogen binding in (i) CRP-XL–stimulated and (ii) thrombin-stimulated platelets. E, 
α-Granule secretion measured as P-selectin exposure in (i) CRP-XL–stimulated and (ii) thrombin-stimulated platelets. Intracellular calcium 
levels determined in FURA-2 AM–loaded platelets after stimulation with (F) CRP-XL (0.25 µg/mL) and (G) thrombin (0.05 U/mL); (i) repre-
sentative traces and (ii) quantified data shown. Data expressed as the percentage of untreated control. Results are mean±SEM for n≥3. 
*P≤0.05 in comparison to vehicle controls.
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aggregation to collagen and thrombin (Figure IB through IE 
in the online-only Data Supplement). As collagen-induced 
platelet aggregation is partially dependent on the release of 
secondary mediators and RXR agonists have been shown to 
inhibit platelet responses to ADP and thromboxane A2,5 we 
determined whether the inhibitory effects of the RXR ago-
nists were because of their ability to inhibit secondary media-
tor signaling. The effects of 9-cis-RA on collagen-evoked 
aggregation were found to be additive to the inhibition caused 
by blockade of secondary mediator signaling and suggested 
that 9-cis-RA was able to inhibit collagen-evoked signaling 
directly (Figure IF in the online-only Data Supplement).
Currently available antagonists for RXR, including HX531, 
are classified by their ability to inhibit the genomic functions of 
the receptor, and it is unknown how they affect the nongenomic 
actions of RXR. End point aggregation assays were performed 
in 96-well microtiter plates in the presence or absence of HX531 
(10 and 30 µmol/L) to a range of platelet agonist concentrations 
(Figure IG in the online-only Data Supplement). Interestingly, 
HX531 caused inhibition of platelet aggregation after stimula-
tion by collagen, thrombin, and the thromboxane A2 receptor 
agonist U46619, which is similar to the inhibition observed pre-
viously by 9-cis-RA, docosahexaenoic acid, and methoprene 
acid. HX531 binds to the same binding pocket in the RXR 
receptor as the 2 RXR agonists 9-cis-RA and methoprene acid. 
Although HX531 functions to block the DNA-binding ability 
of the RXR receptor, it is possible that alteration of the DNA-
binding region is not involved in the nongenomic functions 
of this receptor, whereas other conformational changes that 
occur after ligand interaction with the binding pocket may be 
involved. These findings suggest that HX531 acts as an agonist 
and not an antagonist of the nongenomic functions of RXR.
RXR Agonists Reduce Integrin 
Activation and α-Granule Secretion
Platelet inside-out signaling is essential for activation of inte-
grin αIIbβ3 which supports aggregation by enabling integrin 
binding to fibrinogen and von Willebrand factor. Secretion of 
platelet granule contents amplifies platelet activation through 
recruitment of surrounding platelets, enhancing thrombus for-
mation. To determine whether RXR ligands alter the activation 
of integrin αIIbβ3 and α-granule secretion, fibrinogen binding 
and P-selectin exposure (a marker of α-granule secretion) 
on platelets pretreated with RXR ligands were determined in 
CRP-XL (0.25 μg/mL) and thrombin (0.05 U/mL)–stimulated 
platelets (Figure 2D and 2E). Consistent with the inhibition of 
platelet aggregation, fibrinogen binding and P-selectin expo-
sure to both agonists was inhibited in 9-cis-RA–treated platelets 
compared with controls. Maximum inhibition of both fibrino-
gen binding (50% CRP-XL and 25% thrombin) and P-selectin 
exposure (20%–25% to either agonist) observed at the high-
est concentration of 9-cis-RA (20 µmol/L; Figure 2D and 2E). 
Similar results were obtained after treatment with methoprene 
acid (Figure IIA and IIB in the online-only Data Supplement).
9-cis-RA Inhibits Elevation of Intracellular Calcium
Elevation of cytosolic Ca2+ levels is a critical event in platelet 
activation and is stimulated by both collagen and thrombin, 
although via distinct mechanisms.26 As shown in Figure 2F 
and 2G, treatment with 9-cis-RA resulted in a reduction in 
peak cytosolic calcium levels of 25% after stimulation with 
CRP-XL (20 µmol/L 9-cis-RA) and ≈50% after thrombin 
stimulation in comparison to vehicle control. Treatment with 
methoprene acid had similar effects (Figure IIC and IID in the 
online-only Data Supplement). These observations indicate 
that RXR agonists are able to inhibit Ca2+ elevation evoked by 
both of these platelet agonists, despite the distinct signaling 
pathways that are activated by them.
RXR Ligands Negatively Regulate 
Outside-In Signaling
Given that RXR agonists have broader inhibitory effects than 
initially appreciated, the effect of the RXR agonists on adhe-
sion to fibrinogen and outside-in signaling evoked by integrin 
αIIbβ3 was also investigated. After treatment with 9-cis-RA 
(10 and 20 µmol/L), both adhesion and spreading on fibrino-
gen-(100 µg/mL)–coated coverslips were found to be inhibited 
in 9-cis-RA–treated samples compared with vehicle-treated 
controls (Figure 3A). Similar effects on adhesion and spreading 
on fibrinogen were observed after treatment with docosahexae-
noic acid (Figure IIIA in the online-only Data Supplement).
Outside-in signaling is also essential for the regulation of 
clot retraction, which is required for thrombus stabilization. 
Consistent with the inhibition of adhesion and spreading on 
fibrinogen, treatment of platelets with 9-cis-RA resulted in an 
inhibition of clot retraction because clot weight was increased 
after treatment with 9-cis-RA compared with vehicle-treated 
controls (Figure 3B). Similar observations for docosahexae-
noic acid and methoprene acid support the notion that the 
effect on clot retraction is mediated by RXR activity (Figure 
IIIB in the online-only Data Supplement).
RXR Ligands Inhibit Thrombus 
Formation on Collagen Under Flow
As we have shown that RXR ligands affect several aspects 
of platelet activation, the effect of the 9-cis-RA on throm-
bus formation was assessed in vitro. Human whole blood 
was perfused over collagen-coated (100 μg/mL) Vena8 bio-
chips for 10 minutes at an arterial shear rate of 20 dynes/cm2. 
Consistent with the observed inhibition of platelet activity, 
a significant reduction in thrombus formation (≈35%) was 
observed in 9-cis-RA–treated whole blood in comparison to 
vehicle-treated control samples (Figure 4A). To determine 
whether this inhibition of thrombus formation was because of 
a reduction in the ability of platelets to adhere to collagen, 
platelets were treated with integrilin, an antagonist of integ-
rin αIIbβ3, to prevent platelet–platelet interactions. As shown 
in Figure 4B, no significant difference in platelet adhesion 
on collagen was observed in platelets treated with 20 µmol/L 
9-cis-RA compared with vehicle-treated controls, suggesting 
that 9-cis-RA does not affect adhesion to collagen under flow 
but instead inhibits thrombus growth. This was further sup-
ported by observations under static conditions, where treat-
ment with 9-cis-RA resulted in an inhibition of the ability of 
platelets to spread on collagen-coated coverslips, but adhesion 
to collagen was not significantly altered (Figure IIIC).
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RXR Ligands Inhibit Hemostasis 
and Thrombosis in Mice
To determine the impact of RXR ligands on the acute regu-
lation of platelet function in vivo, the effect of 9-cis-RA on 
laser-induced thrombosis in mouse cremaster muscle arte-
rioles was explored. Figure 4C shows that although the ini-
tial kinetics of thrombus formation were similar, thrombi 
formed in 9-cis-RA–treated mice were consistently smaller 
(≈35%) than those formed after treatment with vehicle con-
trol (0.1% dimethyl sulfoxide; Figure 4Cii and 4Ciii). These 
results suggest an antithrombotic effect of RXR ligands in 
vivo. 9-cis-RA was also found to impair hemostasis in vivo 
as a significant increase in time to cessation of bleeding was 
seen after removal of the tail tip of mice treated with 9-cis-RA 
compared with vehicle control (Figure 4D).
9-cis-RA Does Not Modulate Early 
GPVI Signaling Events
We have shown that platelet activation after stimulation by 
GPVI agonists and thrombin is reduced after treatment with 
RXR ligands. To determine whether this was because of alter-
ations in early signaling events, the phosphorylation levels of 
different signaling proteins involved in the GPVI and thrombin-
signaling pathways were analyzed. Washed human platelets 
were pretreated with 9-cis-RA (10 and 20 µmol/L) or vehicle 
for 10 minutes before stimulation for 5 minutes by CRP-XL 
(1 µg/mL) or thrombin (0.1 U/mL). Higher concentrations 
of platelet agonists were used to enable phosphorylation of 
signaling components to be detected by Western blotting. 
Interestingly, despite the observed inhibition of platelet func-
tions and thrombus formation, total tyrosine phosphorylation 
and phosphorylation of Syk and PLCγ2 (phospholipase C) 
after stimulation by CRP-XL were not altered by treatment 
with 9-cis-RA (10 and 20 µmol/L; Figure IVA and IVB in 
the online-only Data Supplement). PKC (protein kinase C) 
activity was also assessed using an antibody raised against 
the phosphorylated PKC substrate recognition sequence. PKC 
activity after stimulation by either CRP-XL or thrombin for 5 
minutes was unaffected by treatment with 9-cis-RA (Figure 
IVC and IVD in the online-only Data Supplement) but was 
reduced at earlier time points, with inhibition observed at 90 
seconds (CRP-XL) and 30 seconds (thrombin). These obser-
vations indicate that the RXR agonists cause a reduction in the 
rate but not the magnitude of PKC activation.
9-cis-RA Increases PKA Activity in 
Resting and Stimulated Platelets
The data presented here demonstrates a role for RXR in the 
negative regulation of platelet function, although this is not 
associated with prominent alterations in the early platelet 
signaling events associated with GPVI agonists or thrombin. 
Such broad effects are unlikely to be explained by inhibition 
of specific elements of activation pathways; therefore, acti-
vation of inhibitory pathways was investigated. Treatment 
Figure 3. The effect of 9-cis-retinoic acid (9-cis-RA) on integrin αIIbβ3 outside-in signaling. Human washed platelets pretreated for 10 
min with increasing concentrations of 9-cis-RA (10 and 20 µmol/L) or vehicle control were exposed to fibrinogen (100 µg/mL) coated 
coverslips. A (i) representative images of spreading and adhesion after 45 min. Platelets were stained with phalloidin Alexa-488 for visu-
alization. Images were taken under oil immersion with magnification ×100. (ii) Adhesion: the number of platelets adhered were counted in 
5 randomly selected fields of view, and the number of cells adhered were expressed as the percentage of the vehicle-treated control. (iii) 
Spreading platelets were classified into 3 different categories to determine the extent of their spreading (adhered but not spread; filopo-
dia: platelets in the process of extending filopodia and lamellipodia: platelets in the process of extending lamellipodia including those fully 
spread). Results expressed (as relative frequency) as the percentage of the total number of platelets adhered. B, Clot retraction: human 
washed platelets pretreated for 10 min with increasing concentrations of 9-cis-RA (10 and 20 µmol/L) or vehicle control were added to 
aggregometer tubes in the presence of 2 mg/mL fibrinogen and 2 mmol/L CaCl2. Clot retraction was initiated by addition of thrombin 1 
U/mL (final concentration) and left to proceed for 1 h at room temperature. Extent of clot retraction was determined by comparing clot 
weight. (i) Representative images using red blood cell stained platelet-rich plasma, (ii) data expressed as clot weight (mg). Unless stated 
otherwise, results are mean±SEM for n≥3. *P≤0.05 in comparison to vehicle controls.
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of platelets with ligands for PPARs has previously been 
described to cause upregulation of PKA activity in some cases 
via increasing intracellular levels of cAMP.2,4,12,27 As we have 
identified that both PPARα and PPARγ can heterodimerize 
with RXR in platelets, we determined whether or not RXR 
agonists were capable of altering PKA activity.
To determine whether RXR agonists altered PKA activity, 
VASP (vasodilator-stimulated phosphoprotein) S157 phos-
phorylation (a PKA-specific phosphorylation site and marker 
of PKA activity) was measured. Unstimulated platelets treated 
with 9-cis-RA (10 and 20 µmol/L; Figure 5A) or methoprene 
acid (Figure V in the online-only Data Supplement; 10 and 
20 µmol/L) showed increased phosphorylation of VASP S157 
in comparison to untreated controls. 9-cis-RA–dependent 
increase in VASP S157 phosphorylation was prevented after 
treatment with 2 different PKA inhibitors H89 (10 µmol/L) 
and Rp-8-CPT-cAMPs (100 µmol/L; Figure 5A). Similar 
results were also observed after treatment with either doco-
sahexaenoic acid or methoprene acid because both alterna-
tive RXR ligands also caused a significant increase in VASP 
S157 phosphorylation that was reversed after treatment with 
the PKA inhibitor H89 (Figure V in the online-only Data 
Supplement).
It has been shown that VASP can also be phosphorylated 
and regulated in platelets by the PKC isoforms and PKB/
Akt. However, treatment with either a pan-PKC inhibitor 
GF109203X (10 µmol/L) or AKT inhibitor, AKT inhibitor IV 
(5 µmol/L), did not prevent the 9-cis-RA–induced increases 
in VASP S157 phosphorylation (Figure VI in the online-only 
Data Supplement), providing further support that RXR ago-
nists exert their effect through PKA.
Activation of PKA has been shown to result in the nega-
tive regulation of the family of Rho GTPases including RhoA 
and Rac1 that have been identified as key regulators of platelet 
Figure 4. The effect of retinoid X receptor (RXR) ligands on thrombus formation in vitro and in vivo. A and B, DiOC6-loaded human 
whole blood was pretreated with vehicle (black) or 20 µmol/L 9-cis-retinoic acid (9-cis-RA; dotted) in the absence (A) or presence (B) of 
10 µmol/L integrilin for 10 min before perfusion through collagen-coated (100 µg/mL) Vena8Biochips at an arterial shear rate of 20 dyn/
cm2. Thrombus formation was determined after 10 min (A) or 3 min (B) by comparing fluorescence intensity in the vehicle- and 9-cis-RA–
treated samples. (ii) Data expressed as percentage of vehicle control, where maximum fluorescence observed in vehicle-treated platelets 
is considered to be 100% thrombus formation. (iii) Data expressed as % of vehicle control after 10-min thrombus formation. C, In vivo 
thrombosis was assayed by intravital microscopy using the laser-induced injury model. 9-cis-RA (estimated concentration 20 µmol/L) 
or vehicle (0.1% v/v dimethyl sulfoxide) was administered intravenously to mice, and platelets were fluorescently labeled with Alexa-
488–conjugated anti-GPIb antibody. After laser injury, platelet accumulation and thrombus formation was assessed. (i) Representative 
images are shown, and data expressed as (ii) median thrombus area over time, and (iii) thrombus size determined by calculating the area 
under the curve. Between 8 and 10 thrombi were analyzed from 4 mice treated for each condition. D, Tail bleeding as determined as time 
to cessation of bleeding in mice pretreated with vehicle or 20 µmol/L 9-cis-RA for 10 min (n=10 for vehicle-treated and 9 for 9-cis-RA–
treated samples). Unless stated otherwise, results are mean±SEM for n≥3. *P≤0.05 in comparison to vehicle controls.
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function. Negative regulation of RhoA, in turn, negatively regu-
lates cytoskeleton rearrangements and phosphorylation of the 
myosin light chain. In further support of the inhibition of plate-
let function by 9-cis-RA being caused by an increase in PKA 
activity, we observed an inhibition of myosin light chain phos-
phorylation at Ser19 in both thrombin-treated (0.1 U/mL) and 
CRP-treated (1 µg/mL) platelets after treatment with 9-cis-RA 
(10 and 20 µmol/L) compared with vehicle controls (Figure 5B).
Figure 5. Retinoid X receptor (RXR) ligands and protein kinase A (PKA) activity. Resting human washed platelets were treated with 9-cis-
retinoic acid (9-cis-RA; 10 and 20 µmol/L) in the presence or absence of (A) PKA inhibitors (i) H89 (10 μmol/L) or (ii) Rp-8-CPT-cAMPs (100 
µmol/L) for 10 min and samples tested for VASP S157 phosphorylation, a marker of PKA activity. PGI2, which activates platelets through 
binding to the prostaglandin receptor (IP receptor) leading to activation of adenylyl cyclase, was included as a positive control for PKA 
activation. i and ii, Representative blots are shown and (iii) levels of phosphorylation were quantified and expressed as fold increase com-
pared with vehicle control. B, Thrombin-stimulated (0.1 U/mL) or CRP-stimulated (1 µg/mL) platelets (0- and 180-s stimulation) pretreated 
with 9-cis-RA (10 and 20 µmol/L) were analyzed for myosin light chain (MLC) Ser19 phosphorylation. C, CRP-stimulated (1 µg/mL) or (D) 
thrombin-stimulated (0.1 U/mL) platelets (0, 15, 30, 60, 90, 180, and 300 s of stimulation) pretreated with 9-cis-RA (20 µmol/L) were also 
analyzed for VASP S157 phosphorylation. Blotting samples were lysed in Laemmli sample buffer before separation by SDS–PAGE and 
transferred onto polyvinylidene fluoride (PVDF) membranes. Actin was used as a loading control. i, Representative blots are shown and (ii) 
levels of phosphorylation were quantified and expressed as fold increase compared with vehicle control. Results are mean±SEM for n≥3. 
*P≤0.05 in comparison to vehicle controls.
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To investigate whether PKA activity was also altered in 
agonist-stimulated platelets, human washed platelets were 
pretreated with 9-cis-RA (20 µmol/L) before stimulation 
with CRP-XL (1 µg/mL) or thrombin (0.1 U/mL), and VASP 
S157 phosphorylation monitored over a period of 5 minutes. 
A time-dependent increase in VASP S157 phosphorylation 
was observed in both CRP-XL–stimulated and thrombin-
stimulated platelets as has been described previously.24 As 
shown in Figure 5C and 5D VASP S157 phosphorylation was 
significantly increased in 9-cis-RA–treated platelets before 
stimulation with either CRP-XL or thrombin and remained 
significantly higher than vehicle control at early time points. 
At later time points, no significant difference in VASP S157 
phosphorylation was observed in 9-cis-RA–treated platelets 
compared with controls. This suggests that RXR agonists may 
exert their inhibitory effects via elevation of PKA activity, 
whereas CRP and thrombin activate PKA as a form of nega-
tive feedback once platelet activation has occurred.
RXR Ligand–Mediated Increases in PKA Activity 
Are Dependent on Adenylyl Cyclase Activity 
but Not Prostaglandin I2 Receptor Signaling
Traditionally, activation of PKA occurs after the production 
of cAMP downstream of prostaglandin I2 (IP) receptor sig-
naling. Binding of PGI2 to the IP receptor causes Gs-coupled 
signaling that activates adenylyl cyclase and stimulates 
the production of cAMP, which then activates PKA. RXR 
ligand–mediated increases in PKA activity were found to 
be independent of IP receptor activation, as the IP receptor 
antagonist Ro1138452 (10 µmol/L)28,29 was unable to reverse 
9-cis-RA–mediated increases in VASP S157 phosphoryla-
tion (Figure 6A). However, RXR ligand–dependent activation 
of PKA was attenuated after treatment with SQ22536 (100 
µmol/L), an adenylyl cyclase inhibitor, because 9-cis-RA–
mediated (and docosahexaenoic acid–mediated) increases in 
VASP S157 phosphorylation were reduced after pretreatment 
with SQ22536 (Figure 6B). Interestingly, however, under the 
same experimental conditions, treatment with 9-cis-RA did not 
alter cAMP levels in resting platelets (Figure 6Ci). In the pres-
ence of the phosphodiesterase inhibitor, IBMX (1 mmol/L), 
a minor increase in cAMP was observed after treatment with 
9-cis-RA (Figure 6Cii) but not after treatment with metho-
prene acid or docosahexaenoic acid (Figure VIIA and VIIB 
in the online-only Data Supplement). These data suggest that 
RXR ligand–dependent increases in VASP S157 phosphoryla-
tion and PKA activity are dependent on intracellular cAMP 
but not associated with significant increases in cAMP levels.
9-cis-RA–Induced Increases in PKA Activity 
Are Associated With NFκB Activity
In addition to cAMP-mediated activation of PKA, PKA has 
also been shown to be activated via a mechanism that is depen-
dent on NFκB, after stimulation of platelets by thrombin or 
collagen.24 In this mechanism, a subpopulation of PKA is 
associated with NFκB–IκBα and after stimulation by collagen 
or thrombin, NFκB is activated, leading to degradation and 
release of IκBα.30 This enables dissociation of the catalytic 
subunit of PKA from NFκB–IκBα, resulting in the activation 
of PKA. To investigate whether RXR agonists activate PKA 
via NFκB–IκBα, we treated platelets with IKK inhibitor VII 
(5 μmol/) to determine whether it was able to reverse the 
observed platelet inhibition. IKK inhibitor VII was used pre-
viously to establish the role of NFκB in PKA activation and 
prevents the degradation and release of IκBα. IKK inhibitor 
VII prevented 9-cis-RA–induced VASP S157 phosphoryla-
tion in resting platelets, highlighting a role for the activation 
of NFκB and dissociation of IκBα in RXR-ligand–induced 
regulation of PKA activity (Figure 6D). Similar observations 
were also made after treatment with docosahexaenoic acid and 
methoprene acid (Figure VIIC and VIID in the online-only 
Data Supplement). Furthermore, treatment with a proteasome 
inhibitor, MG132 (10 µmol/L), used to prevent degradation 
of IκBα, also prevented 9-cis-RA–induced phosphorylation 
of VASP S157 (Figure 6E). Both H89 and the IKK inhibitor, 
but not SQ22536 the adenylyl cyclase inhibitor, were found 
to reverse 9-cis-RA–mediated inhibition of platelet spreading 
on fibrinogen and clot retraction, implicating RXR-dependent 
upregulation of NFκB–IκBα and PKA in the negative regula-
tion of platelet αIIbβ3 outside-in signaling (Figure 6F and 6G).
We have previously described that PPARγ ligands are 
capable of negatively regulating integrin αIIbβ3 outside-
in signaling through upregulation of PKA activity.12 As we 
found PPARγ can be coimmunoprecipitated with RXR from 
platelets, we determined whether it is the activation and mod-
ulation of RXR:PPARγ heterodimers that regulates the NFκB-
mediated upregulation of PKA activity. However, the IKK 
inhibitor was unable to reverse 15dPGJ2-mediated (an endog-
enous ligand for PPARγ) increases in VASP S157 phosphor-
ylation (Figure VIIIA in the online-only Data Supplement), 
suggesting that PPARγ-dependent increases in PKA activity 
are not linked to the regulation of NFκB. In further support of 
this, the IKK inhibitor was also unable to reverse the increase 
in VASP S157 phosphorylation and PKA activity observed 
after treatment with the RXR modulator LG101506, which 
specifically modulates RXR:PPAR heterodimers (Figure 
VIIIB in the online-only Data Supplement). This suggests that 
ligands of RXR and PPARγ upregulate PKA activity via dif-
ferent mechanisms.
Discussion
RXRs are intracellular nuclear receptors expressed in human 
platelets where they function to negatively regulate plate-
let responses to agonists.3,4,11,21 In its genomic role, RXR is 
thought to heterodimerize with several intracellular nuclear 
receptors including PPARs, LXR, and FXR and is, therefore, 
also associated with the regulation of glucose, triglyceride, 
cholesterol, and bile acid homeostasis.20 Dysregulation of 
these homeostatic control pathways can result in several met-
abolic disorders including obesity, type 2 diabetes mellitus, 
hyperlipidemia, atherosclerosis, and cardiovascular disease. 
Treatment with RXR ligands shows some efficacy at reducing 
the progression of atherosclerosis in apolipoprotein E knock-
out mice.18 Alitretinoin, the commercial name for RXR ligand 
9-cis-RA, is used for the treatment of Kaposi sarcoma and 
eczema, and decreased blood clotting is currently listed as one 
of its side effects.18,22,23 In support of the ability of 9-cis-RA to 
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reduce blood clotting, we show that treatment with 9-cis-RA 
increases bleeding time in mice and elicits other antithrom-
botic effects, which we attribute to an activation of PKA via a 
mechanism that requires cAMP and involves NFκB. As plate-
lets play an important role in the pathogenesis of cardiovas-
cular disease, our findings that RXR ligands inhibit platelet 
activation and thrombus formation may help to explain the 
efficacy of these compounds in vivo.
We observed that treatment of platelets with RXR agonists 
9-cis-RA, methoprene acid, and docosahexaenoic acid caused 
a significant inhibition of α-granule secretion; mobilization 
of intracellular calcium; platelet aggregation and integrin 
αIIbβ3 activation to several platelet agonists including col-
lagen, CRP-XL, and thrombin; and an inhibition of integrin 
αIIbβ3 outside-in signaling. This inhibition of platelet activ-
ity by 9-cis-RA also correlated with inhibition of thrombus 
formation in vitro and in vivo, suggesting that the previously 
described cardioprotective effects of RXR agonists in reduc-
ing atherosclerosis18 could also potentially be attributed to 
their negative regulation of platelet function.
Treatment of platelets with ligands for PPARs, PPARα 
and PPARβ/δ or PPARγ common binding partners for RXR 
Figure 6. 9-cis-retinoic acid (9-cis-RA)–dependent increase in protein kinase A (PKA) activity is dependent on cAMP and nuclear fac-
tor κ-light-chain-enhancer of activated B cell (NFκB). Resting human washed platelets were treated with 9-cis-RA (10 and 20 µmol/L) 
in the presence or absence of (A) IP receptor antagonist Ro1138452 (10 µmol/L), (B) adenylyl cyclase inhibitor SQ22536 (100 µmol/L), 
(D) IKK inhibitor (5 μmol/L), or (E) proteasome inhibitor MG132 (10 μmol/L) for 10 min, and samples tested for VASP S157 phosphoryla-
tion, a marker of PKA activity. Blotting samples were lysed in Laemmli sample buffer before separation on SDS–PAGE and transferred 
onto polyvinylidene fluoride (PVDF) membranes. Actin was used as a loading control. (i) Representative blots are shown and (ii) levels of 
phosphorylation were quantified and expressed as fold increase compared with vehicle control. C, Levels of cAMP were determined in 
9-cis-RA–treated (10 and 20 µmol/L) resting washed platelets using a cAMP ELISA assay kit (as per manufacturer’s instructions) in the 
(i) absence and (ii) presence of IBMX (1 mmol/L). PGI2 was included as a positive control for PKA activation and intracellular increases 
in cAMP. F and G, Human washed platelets were treated with 9-cis-RA (20 µmol/L) in the presence or absence of H89 (10 µmol/L), IKK 
inhibitor (5 μmol/L) or SQ22536 (100 μmol/L) for 10 min (F) before exposure to fibrinogen-coated (100 µg/mL) coverslips and left to 
spread and adhered for 45 min. Data presented as average platelet size as calculated by looking at individual platelet surface area of 
platelets adhered in 5 randomly selected fields of view using ImageJ software. The larger the surface area, the more spread the platelet is. 
G, In the presence of 2 mg/mL fibrinogen and 2 mmol/L CaCl2, in aggregometer tubes, clot retraction was initiated by addition of throm-
bin 1 U/mL (final concentration) and left to proceed for 1 h at room temperature. Extent of clot retraction was determined by comparing 
clot weight. Results are mean±SEM for n≥3. *P≤0.05 in comparison to vehicle controls.
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(Figure 1) have been previously described to cause upregula-
tion of cAMP levels or activation of PKA. RXR ligand–stim-
ulated inhibition of platelet function and thrombus formation 
were also found to be associated with an upregulation of PKA 
activity, as treatment of platelets with RXR agonists resulted 
in an increase in VASP phosphorylation at S157 (the PKA 
phosphorylation site) in both resting and agonist-stimulated 
platelets, and this increase was reversed after treatment with 
the PKA inhibitors H89 and Rp-8-CPT-cAMPs or adenylyl 
cyclase inhibitor SQ22358 but not after treatment with an IP 
receptor antagonist (Ro1138452). This suggests that RXR 
agonists activate PKA through a mechanism that is dependent 
on cAMP, although no major alterations in cAMP levels were 
observed after treatment with the different RXR agonists. It is 
possible that treatment with RXR agonists does cause small 
increases in platelet cAMP levels that are not detected given 
current limitations in sensitivity of the assays used. It has been 
shown that even minor increases in cAMP levels can cause 
significant activation of cellular PKA and large increases 
in VASP S157 phosphorylation.31 As such, a role for RXR 
ligands in the upregulation of adenylyl cyclase activity can-
not be ruled out. It is, however, interesting to note that RXR 
ligand–mediated inhibition of integrin αIIbβ3 outside-in sig-
naling cannot be reversed by inhibition of adenylyl cyclase, 
suggesting a role for another PKA-linked signaling pathway 
in this negative regulation of platelet function.
It has been previously shown that activation of NFκB is 
involved in regulation of PKA activity after platelet activa-
tion by collagen or thrombin, where the inactive NFκB–IκBα 
complex binds to and inactivates the PKA catalytic subunit.24 
In cancer cells, activation of NFκB has also been shown to 
occur after treatment with RXR ligands, including 9-cis-RA, 
and inhibition or downregulation of NFκB has been shown 
to reduce RXR-mediated cell differentiation and apoptosis of 
cancerous cells.32 We, therefore, hypothesized that treatment 
with RXR ligands could enable targeted degradation of the 
inactive NFκB–IκBα complex, releasing the PKA catalytic 
subunit and relieving the inhibition of PKA, resulting in an 
increase in PKA activity and subsequent substrate phosphory-
lation. This was supported by observations that treatment with 
H89 and the IKK inhibitor prevented 9-cis-RA–mediated 
upregulation of PKA activity and also reversed 9-cis-RA–
mediated inhibition of platelet spreading on fibrinogen and 
clot retraction, which is dependent on integrin αIIbβ3 outside-
in signaling. It is interesting to note, however, that the upregu-
lation of PKA activity via NFκB is not a mechanism that is 
shared with the PPARs, typical binding partners of RXR, as 
the increase in VASP S157 phosphorylation observed after 
treatment with the RXR:PPAR modulator LG101506 could 
not be reversed by pretreatment with the IKK inhibitor.
Activation of PKA has been shown to negatively regulate 
the family of Rho GTPases including RhoA and Rac1.24,33,34 
Rho GTPases including Rac1 are key mediators of platelet 
function, and mice deficient in Rac1 display major defects in 
platelet activation downstream of both GPVI and GPCRs and 
reduced thrombus formation in vivo.35–37 Previously published 
work suggests that Rac1 activity is reduced after treatment of 
platelets with RXR ligands, and this is attributed to an interac-
tion of RXR with Gq.5 In agreement with alteration of RhoA 
activity, a reduction in myosin light chain phosphorylation 
was observed after treatment with 9-cis-RA. The upregulation 
of PKA activity that we describe here could also provide an 
additional mechanism that underlies this reduction in Rac1 
activity that may explain the broad-spectrum inhibition by 
RXR ligands of platelet activity to multiple platelet agonists. 
Because RXR has the potential to form heterodimers with 
several different nuclear receptors, multiple mechanisms of 
regulation could exist.
The data presented here significantly build on previously 
observed inhibitory effects of RXR ligands on platelet activ-
ity5 and highlight a relatively unknown mechanism of PKA 
activation as a potential target for antiplatelet therapy. The 
data presented here suggest that RXR ligands could offer extra 
protective effects in vivo if developed as drug targets for the 
treatment of other diseases such as diabetes mellitus, although 
these effects would need to be carefully balanced to ensure 
there is no increased risk of bleeding.
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Highlights
• Platelets express the retinoid X receptors (RXRα and RXRβ).RXR ligands cause a widespread inhibition of platelet function to multiple platelet 
agonists.
• RXR ligands inhibit thrombus formation and impair hemostasis.
• This nongenomic regulation by RXR ligands is mediated by activation of PKA that involves cAMP and nuclear factor κ-light-chain-enhancer of 
activated B cell.
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